Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Bart Barlogie, Mauricio Pineda-Roman, Frits Van Rhee, Jeff Haessler, Elias Anaissie, Klaus Hollmig, Yazan Alsayed, Sarah Waheed, Nathan Petty, Joshua Epstein, John D. Shaughnessy, Guido Tricot, Maurizio Zangari, Jerome Zeldis, Sol Barer, John Crowley

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

Total Therapy 2 examined the clinical benefit of adding thalidomide up-front to a tandem transplant regimen for newly diagnosed patients with multiple myeloma. When initially reported with a median follow-up of 42 months, complete response rate and event-free survival were superior among the 323 patients randomized to thalidomide, whereas overall survival was indistinguishable from that of the 345 patients treated on the control arm. With further follow-up currently at a median of 72 months, survival plots segregated 5 years after initiation of therapy in favor of thalidomide (P=.09), reaching statistical significance for the one third of patients exhibiting cytogenetic abnormalities (CAs; P=.02), a wellrecognized adverse prognostic feature. The duration of complete remission was also superior in the cohort presenting with CAs such that, at 7 years from onset of complete remission, 45% remained relapse-free as opposed to 20% on the control arm (P=.05). These observations were confirmed when examined by multivariate analysis demonstrating that thalidomide reduced the hazard of death by 41% among patients with CA-positive disease (P=.008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well,

Original languageEnglish (US)
Pages (from-to)3115-3121
Number of pages7
JournalBlood
Volume112
Issue number8
DOIs
StatePublished - Oct 15 2008

Fingerprint

Thalidomide
Metaphase
Chromosome Aberrations
Arm
Survival
Therapeutics
Transplants
Multiple Myeloma
Hazards
Disease-Free Survival
Multivariate Analysis
Recurrence

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Barlogie, B., Pineda-Roman, M., Van Rhee, F., Haessler, J., Anaissie, E., Hollmig, K., ... Crowley, J. (2008). Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood, 112(8), 3115-3121. https://doi.org/10.1182/blood-2008-03-145235

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. / Barlogie, Bart; Pineda-Roman, Mauricio; Van Rhee, Frits; Haessler, Jeff; Anaissie, Elias; Hollmig, Klaus; Alsayed, Yazan; Waheed, Sarah; Petty, Nathan; Epstein, Joshua; Shaughnessy, John D.; Tricot, Guido; Zangari, Maurizio; Zeldis, Jerome; Barer, Sol; Crowley, John.

In: Blood, Vol. 112, No. 8, 15.10.2008, p. 3115-3121.

Research output: Contribution to journalArticle

Barlogie, B, Pineda-Roman, M, Van Rhee, F, Haessler, J, Anaissie, E, Hollmig, K, Alsayed, Y, Waheed, S, Petty, N, Epstein, J, Shaughnessy, JD, Tricot, G, Zangari, M, Zeldis, J, Barer, S & Crowley, J 2008, 'Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities', Blood, vol. 112, no. 8, pp. 3115-3121. https://doi.org/10.1182/blood-2008-03-145235
Barlogie, Bart ; Pineda-Roman, Mauricio ; Van Rhee, Frits ; Haessler, Jeff ; Anaissie, Elias ; Hollmig, Klaus ; Alsayed, Yazan ; Waheed, Sarah ; Petty, Nathan ; Epstein, Joshua ; Shaughnessy, John D. ; Tricot, Guido ; Zangari, Maurizio ; Zeldis, Jerome ; Barer, Sol ; Crowley, John. / Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. In: Blood. 2008 ; Vol. 112, No. 8. pp. 3115-3121.
@article{2869f3872a9a4dbb8b45c354cc875208,
title = "Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities",
abstract = "Total Therapy 2 examined the clinical benefit of adding thalidomide up-front to a tandem transplant regimen for newly diagnosed patients with multiple myeloma. When initially reported with a median follow-up of 42 months, complete response rate and event-free survival were superior among the 323 patients randomized to thalidomide, whereas overall survival was indistinguishable from that of the 345 patients treated on the control arm. With further follow-up currently at a median of 72 months, survival plots segregated 5 years after initiation of therapy in favor of thalidomide (P=.09), reaching statistical significance for the one third of patients exhibiting cytogenetic abnormalities (CAs; P=.02), a wellrecognized adverse prognostic feature. The duration of complete remission was also superior in the cohort presenting with CAs such that, at 7 years from onset of complete remission, 45{\%} remained relapse-free as opposed to 20{\%} on the control arm (P=.05). These observations were confirmed when examined by multivariate analysis demonstrating that thalidomide reduced the hazard of death by 41{\%} among patients with CA-positive disease (P=.008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well,",
author = "Bart Barlogie and Mauricio Pineda-Roman and {Van Rhee}, Frits and Jeff Haessler and Elias Anaissie and Klaus Hollmig and Yazan Alsayed and Sarah Waheed and Nathan Petty and Joshua Epstein and Shaughnessy, {John D.} and Guido Tricot and Maurizio Zangari and Jerome Zeldis and Sol Barer and John Crowley",
year = "2008",
month = "10",
day = "15",
doi = "10.1182/blood-2008-03-145235",
language = "English (US)",
volume = "112",
pages = "3115--3121",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

AU - Barlogie, Bart

AU - Pineda-Roman, Mauricio

AU - Van Rhee, Frits

AU - Haessler, Jeff

AU - Anaissie, Elias

AU - Hollmig, Klaus

AU - Alsayed, Yazan

AU - Waheed, Sarah

AU - Petty, Nathan

AU - Epstein, Joshua

AU - Shaughnessy, John D.

AU - Tricot, Guido

AU - Zangari, Maurizio

AU - Zeldis, Jerome

AU - Barer, Sol

AU - Crowley, John

PY - 2008/10/15

Y1 - 2008/10/15

N2 - Total Therapy 2 examined the clinical benefit of adding thalidomide up-front to a tandem transplant regimen for newly diagnosed patients with multiple myeloma. When initially reported with a median follow-up of 42 months, complete response rate and event-free survival were superior among the 323 patients randomized to thalidomide, whereas overall survival was indistinguishable from that of the 345 patients treated on the control arm. With further follow-up currently at a median of 72 months, survival plots segregated 5 years after initiation of therapy in favor of thalidomide (P=.09), reaching statistical significance for the one third of patients exhibiting cytogenetic abnormalities (CAs; P=.02), a wellrecognized adverse prognostic feature. The duration of complete remission was also superior in the cohort presenting with CAs such that, at 7 years from onset of complete remission, 45% remained relapse-free as opposed to 20% on the control arm (P=.05). These observations were confirmed when examined by multivariate analysis demonstrating that thalidomide reduced the hazard of death by 41% among patients with CA-positive disease (P=.008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well,

AB - Total Therapy 2 examined the clinical benefit of adding thalidomide up-front to a tandem transplant regimen for newly diagnosed patients with multiple myeloma. When initially reported with a median follow-up of 42 months, complete response rate and event-free survival were superior among the 323 patients randomized to thalidomide, whereas overall survival was indistinguishable from that of the 345 patients treated on the control arm. With further follow-up currently at a median of 72 months, survival plots segregated 5 years after initiation of therapy in favor of thalidomide (P=.09), reaching statistical significance for the one third of patients exhibiting cytogenetic abnormalities (CAs; P=.02), a wellrecognized adverse prognostic feature. The duration of complete remission was also superior in the cohort presenting with CAs such that, at 7 years from onset of complete remission, 45% remained relapse-free as opposed to 20% on the control arm (P=.05). These observations were confirmed when examined by multivariate analysis demonstrating that thalidomide reduced the hazard of death by 41% among patients with CA-positive disease (P=.008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well,

UR - http://www.scopus.com/inward/record.url?scp=54049148621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049148621&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-03-145235

DO - 10.1182/blood-2008-03-145235

M3 - Article

C2 - 18492953

AN - SCOPUS:54049148621

VL - 112

SP - 3115

EP - 3121

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -